CytoDyn Inc. General form of registration statement for all companies including face-amount certificate companies

General form of registration statement for all companies including face-amount certificate companies

Loss per Common Share (Tables)

Loss per Common Share (Tables)

6 Months Ended

12 Months Ended

Nov. 30, 2023

May 31, 2023

Loss per Common Share

Schedule of reconciliation of the numerators and denominators of basic and diluted net loss per share


		Three months ended November 30,						Six months ended November 30,
(in thousands, except per share amounts)		2023			2022			2023			2022
Net loss		$	(9,563)		$	(26,495)		$	(21,134)		$	(47,486)
Less: Deemed dividends			—			(1,140)			—			(5,294)
Less: Accrued preferred stock dividends			(368)			(370)			(741)			(756)
Net loss applicable to common stockholders		$	(9,931)		$	(28,005)		$	(21,875)		$	(53,536)
Basic and diluted:
Weighted average common shares outstanding			958,988			813,373			941,191			800,545
Loss per share		$	(0.01)		$	(0.03)		$	(0.02)		$	(0.07)


	Fiscal years ended May 31,
(in thousands, except per share amounts)	2023			2022
Net loss	$	(79,824)		$	(210,820)
Less: Deemed dividends		(5,417)			—
Less: Accrued preferred stock dividends		(1,495)			(1,628)
Net loss applicable to common stockholders	$	(86,736)		$	(212,448)
Basic and diluted:
Weighted average common shares outstanding		836,528			676,900
Loss per share	$	(0.10)		$	(0.31)

Schedule of securities excluded from computation of earnings per share


	Three and six months ended November 30,
(in thousands)	2023		2022
Stock options, warrants, and unvested restricted stock units	312,956		204,273
Convertible notes	12,000		12,000
Convertible preferred stock	35,558		32,591


	Fiscal years ended May 31,
(in thousands)	2023		2022
Stock options, warrants, and unvested restricted stock units	281,023		106,002
Convertible notes	12,000		12,000
Convertible preferred stock	34,071		32,535